[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@johnkmason Avatar @johnkmason John Mason

John Mason posts on X about $qure, finance, pricing, $2m the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence finance stocks

Social topic influence $qure #39, finance, pricing, $2m, $qures, $ions, build on, $glng, loading, $700k

Top assets mentioned uniQure N.V. (QURE) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Golar LNG Ltd (GLNG) Cigna Corp (CI) Centene Corp (CNC) UnitedHealth Group (UNH)

Top Social Posts #

Top posts by engagements in the last XX hours

"@cureffi Donation page here:"
X Link @johnkmason 2025-10-09T02:13Z XXX followers, XX engagements

"Was talking to my stepsister who works with pharma as they label/price drugs about $QURE. She pressure-tested my AMT-130 pricing assumptions given she's seen finance folks go into pricing negotiations with rosy estimates but get taken down notch(es) by payers. 🧵"
X Link @johnkmason 2025-10-12T02:08Z XXX followers, 1146 engagements

"@cureffi This was so essential a read re: $QURE and AMT-130 that I downloaded as PDF so as to have it permanently"
X Link @johnkmason 2025-10-09T02:14Z XXX followers, XXX engagements

"Definitely builds confidence in the $2m assumption I have built into my model. Any other challenges/doubts from folks that $QURE will be able to price at $2m Or reasoning backing a higher price @peter_mantas @AB1001_disciple @A_May_MD @seedy19tron"
X Link @johnkmason 2025-10-12T02:08Z XXX followers, XXX engagements

"Also worth noting that $QURE's X main competitors WVE-003 (file/review 2029-2030 SNP3 carriers only) Roche/ $IONS Tominerson (2030+) and Novartis/PTC PTC518 (2029-30) are way behind and any new therapies that build on AMT-130 likely launch post-2031 at the earliest"
X Link @johnkmason 2025-10-04T16:46Z XXX followers, 1298 engagements

"Ok brief break from $QURE poasting but started loading up on $GLNG yesterday and doubled today. Love these sort of "wait for paint to dry" plays. There's an excellent VIC writeup written at these price levels from May too I recommend. Though no idea why it started spiking"
X Link @johnkmason 2025-10-09T18:52Z XXX followers, XXX engagements

"2. Ground-up value estimate FOR insurers based on avoidance of existing cost of treatment over lifetime including LTC. Rough estimate of $700k-$1.5m over lifetime including long-term care"
X Link @johnkmason 2025-10-12T02:08Z XXX followers, XXX engagements

"Source: $CI $CNC $UNH re: ACA rates"
X Link @johnkmason 2025-10-16T04:54Z XXX followers, 1302 engagements

"Believe below is the most recent interview (10/3) Sarah Tabrizi (AMT-130 KOL) has given since $QURE readout. This video literally only has XXX views: alpha Been scouring for bear cases as I have XX% of my NW in this and it presents two: 🧵"
X Link @johnkmason 2025-10-04T16:46Z XXX followers, 27.1K engagements

"re: $CLPT. No dog in the fight but here's why I don't own it. X. I agree $QURE has de-risked $CLPT LT. But I think there is path risk from here to AMT-130 launch in 2027 which will itself take time to ramp. I could absolutely see $CLPT with a XX% drawdown between now and launch. Look at the chart. It's happened before. Think you have to have durable conviction/the appropriate LT hold style to be buying/owning here. X. The Shay Boloors of the world are pumping it now. So there's a degree of momentum factor in it (which absolutely may continue and juice your returns). Totally fair bet to make"
X Link @johnkmason 2025-10-04T23:15Z XXX followers, 1622 engagements

"Predicting near-term demand for P&A is tough because it's based on a decades-long aging well pyramid + more recent dry holes. Well intervention a bit better since driven by more recent wells (e.g. 2015-2020 vintage wells going into 1st/2nd workover windows)"
X Link @johnkmason 2025-07-20T19:17Z XXX followers, XXX engagements

"But overall difficult. And not as sensitive to short-term offshore capex as the rig owners or OSV so the shale decline/offshore revitalization thesis won't accrue to $HLX as much near-term though it certainly will LT"
X Link @johnkmason 2025-07-20T19:17Z XXX followers, XXX engagements

"Assorted read-throughs for the $QURE investment case from this: X. Hearing from Eric that the trial participants and natural history controls were very well matched really lessens the risk in my mind that the FDA quibbles about usage of Enroll-HD as external control"
X Link @johnkmason 2025-10-09T02:35Z XXX followers, 2120 engagements